EU drug authorisation is not a single system with one entry point. Two parallel pathways exist, each with distinct legal bases, procedural owners, and commercial consequences, and choosing the wrong one costs you time, money, and market access. This article gives you a decision-oriented comparison to determine which route fits your product before you commit to a filing strategy.
Two Routes, One Market — Why the Choice Matters
The European Union operates two authorisation systems under different legal instruments. The centralised procedure is governed by Regulation (EC) No 726/2004 and produces a single European Commission decision valid across all 27 EU member states plus Norway, Iceland, and Liechtenstein. National authorisation routes operate under Directive 2001/83/EC and are managed by individual national competent authorities (NCAs), with geographic coverage limited to the countries included in the application.
Route selection shapes your entire go-to-market timeline. A centralised marketing authorisation (MA) gives you uniform label coverage across the EEA from day one. National routes can get you to a single market faster, but scaling across borders requires additional procedural steps. Your choice also determines who you negotiate with post-approval, how you file variations to your Summary of Product Characteristics (SmPC), and how you manage pharmacovigilance obligations including post-authorisation safety studies (PASS).
The EMA Centralised Procedure: Scope and Mandatory Categories
The centralised procedure routes your marketing authorisation application (MAA) to the European Medicines Agency (EMA), where the Committee for Medicinal Products for Human Use (CHMP) conducts scientific assessment. A positive CHMP opinion leads to a European Commission decision granting a single MA. That one decision covers the entire EEA. No separate national filings. No divergent labels.
Mandatory Centralised Scope
Certain product categories must use the centralised procedure. There is no discretion here. Under Regulation (EC) No 726/2004, mandatory scope includes:
- Biotechnology-derived medicines, including monoclonal antibodies and recombinant proteins produced via genetic engineering
- Advanced therapy medicinal products (ATMPs), covering gene therapies, somatic cell therapies, and tissue-engineered products — a CAR-T therapy like axicabtagene ciloleucel falls squarely here
- Orphan medicines designated under Regulation (EC) No 141/2000
- Products for HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune conditions, and other immune dysfunctions
- Products containing a new active substance not authorised in the EU before May 2004 in the above therapeutic areas
If your product sits in any of these categories, the national route is not available to you. Cross-referencing your INN and molecule class against this list is the first step in any EU regulatory strategy document.
Optional Centralised Scope
Products outside mandatory scope can still apply via the centralised procedure if they represent a significant therapeutic, scientific, or technical innovation, or if a centralised authorisation is in the interest of patients at EU level. Optional scope gives you access to the single-label benefit without the legal obligation. If you’re targeting pan-European commercialisation and your product has a credible innovation argument, optional centralised is worth the higher upfront cost.
National Authorisation Routes: Standalone, MRP, and DCP
National authorisation is the right pathway for products outside centralised mandatory scope that are targeting one or a limited number of EU markets. Three variants exist, and the distinction between them matters operationally.
National Procedure
A single-country application assessed by one NCA. Valid only in that member state. Appropriate for generics, well-established use products, or products where your commercial strategy is genuinely single-market. The national procedure runs 210 assessment days, structured similarly to the centralised timeline but without CHMP involvement.
Mutual Recognition Procedure (MRP)
The MRP applies when you already hold a national authorisation in one EU member state, the reference member state (RMS). You then ask one or more concerned member states (CMS) to recognise that existing authorisation. The MRP runs 90 days from the RMS authorisation date. It’s the fastest multi-country route if you’ve already secured one national MA, but it requires that initial single-country approval as a prerequisite.
Decentralised Procedure (DCP)
The DCP is the most common multi-country national route for products without a prior national authorisation. You submit simultaneously across multiple member states, with one acting as RMS. The DCP runs 210 days and can cover as many EU member states as you include from the outset. Label negotiations happen in parallel across all included countries, which can introduce divergence if member states raise objections. Disagreements that can’t be resolved nationally escalate to a coordination group referral, extending timelines.
Timeline and Cost: A Direct Comparison
The centralised procedure runs 210 active assessment days. In practice, clock stops for Day 120 questions (List of Outstanding Issues) and Day 180 responses extend elapsed calendar time to 12-15 months from submission to EC decision for a standard application. Complex products with significant Day 120 queries routinely push toward the longer end of that range.
| Feature | EMA Centralised Procedure | National Authorisation (DCP/MRP) |
|---|---|---|
| Geographic scope | All 27 EU member states + EEA | Selected member states only |
| Assessment days | 210 active days; 12–15 months elapsed | 210 days (DCP); 90 days (MRP) |
| Label uniformity | Single SmPC across EEA | Potential member-state variation |
| Application fees | Six-figure EUR; SME reductions up to 90% | Lower per-country; aggregates with scale |
| Post-approval variations | Single EMA submission | Filed with each NCA separately |
| Mandatory eligibility | Required for biologics, ATMPs, orphans | Available for non-mandatory categories |
EMA centralised fees are substantial. Standard MAA fees run into six figures in euros, though qualifying small and medium enterprises (SMEs) can access fee reductions of up to 90%, and orphan-designated products receive additional fee incentives. If your company qualifies for SME status, the cost differential between centralised and national routes narrows considerably. Map this against your funding runway before assuming national routes are cheaper at scale.
Post-Approval Obligations and Commercial Consequences
A centralised MA generates a single European Public Assessment Report (EPAR) and a uniform SmPC. Post-approval variation management runs through EMA with one submission covering all member states. That administrative efficiency compounds over a product’s lifecycle, particularly for products with active lifecycle management strategies.
National routes fragment post-approval obligations. Each NCA holds its own authorisation file, and variations must be filed separately with each relevant authority. A DCP across eight member states means eight parallel variation submissions for every label update, dose extension, or manufacturing change. For products scaling commercially across the EU, this multiplies regulatory management costs in ways that founders often underestimate at the pre-submission planning stage.
Label divergence is the other downstream risk. DCP negotiations can result in member-state-specific labelling differences, which complicates pan-European marketing materials, pharmacovigilance reporting, and investor-facing regulatory milestone communications. A centralised MA eliminates this risk entirely.
Post-Brexit: What UK-Based Founders Must Plan For
A centralised MA no longer covers Great Britain following the UK’s exit from the EU. UK founders must file separately with the Medicines and Healthcare products Regulatory Agency (MHRA) under the UK national procedure or the MHRA’s international recognition procedure. Northern Ireland retains access to the EU centralised procedure under the Windsor Framework, creating a split regulatory position for UK-based companies with EU ambitions.
Plan EU and UK authorisation strategies in parallel from the outset. Separate dossier management, potentially divergent label outcomes, and distinct post-approval obligations mean that treating UK and EU authorisation as a single workstream will create downstream problems. This is a structural reality of the post-Brexit regulatory environment, not a procedural inconvenience.
Choosing Your Route: A Decision Framework
Which authorisation route is right for your product? Start with mandatory eligibility, then commercial ambition, then resource capacity.
- Mandatory centralised: Biologics, ATMPs, orphan medicines, and products in the defined therapeutic categories under Regulation (EC) No 726/2004 have no choice. Confirm mandatory scope before any other route analysis.
- Optional centralised: Pan-European launch ambition, genuine therapeutic innovation, and the capacity to manage a single complex regulatory relationship all point toward optional centralised. The label uniformity and single post-approval management structure justify higher upfront fees for products with broad EU commercial strategies.
- DCP: Multi-country national route for products outside centralised scope targeting several member states simultaneously without a prior national MA. Appropriate for generics, hybrids, and well-established use products with defined geographic targets.
- MRP: Use when a national MA already exists and you want to extend recognition to additional member states. The 90-day timeline is the fastest multi-country route available, but the prerequisite national authorisation must already be in hand.
- National procedure: Single-market strategy, or speed-to-one-market is the priority over pan-European launch. Generics and products with genuinely limited geographic commercial ambition fit here.
Before finalising your route recommendation, request an EMA eligibility determination if your product sits in an ambiguous category. EMA offers pre-submission meetings specifically to resolve mandatory vs optional scope questions, and engaging that process early prevents costly mid-development strategy reversals. A qualified regulatory affairs professional should validate your route selection against current EMA guidance before you commit to a filing timeline.
Frequently Asked Questions
Is the centralised procedure mandatory for biologics?
Yes. Biotechnology-derived medicines, including monoclonal antibodies and recombinant proteins produced via genetic engineering, fall under the mandatory scope of Regulation (EC) No 726/2004. These products must use the EMA centralised procedure and cannot be authorised via national routes in the EU.
How long does the EMA centralised procedure take?
The centralised procedure runs 210 active assessment days. Clock stops for Day 120 questions and Day 180 outstanding issues extend total elapsed time to 12-15 months from submission to European Commission decision for most applications.
Yes, if the product is outside mandatory centralised scope. Small biotechs with non-biologic products targeting one or two EU markets can use national or DCP routes. SME fee reductions also make the centralised procedure more accessible for qualifying companies than the headline fee suggests.
What is the difference between MRP and DCP?
The mutual recognition procedure (MRP) requires an existing national authorisation in one member state, then extends recognition to additional countries over 90 days. The decentralised procedure (DCP) runs simultaneous submissions across multiple member states from the outset, without a prior national MA, over 210 days.
You can extend coverage via MRP using your existing national MA as the reference. Products not in mandatory centralised scope can build geographic reach incrementally this way, though each expansion adds regulatory management complexity and does not produce the label uniformity of a centralised MA.
Route selection decisions should be validated with a qualified regulatory affairs professional or through direct EMA pre-submission engagement. This article provides strategic orientation, not regulatory advice specific to your product.
